November 9, 2015 : Episode 1

Video

Adjuvant Ipilimumab Approval, Two Breakthrough Designations, and More

Related Videos
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Related Content
Martin Wermke, MD
October 10th 2024

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Meredith McKean, MD, of Sarah Cannon Research Institute
September 16th 2024

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Caroline Robert, MD, PhD
September 15th 2024

RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma

Caroline Robert, MD, PhD
September 15th 2024

Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma